Celldex Therapeutics, Inc. (CLDX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 730,000 | 695,000 | - | |
| Research and development | 54,196,000 | 52,614,000 | - | |
| General and administrative | 10,391,000 | 10,820,000 | - | |
| Total operating expenses | 64,587,000 | 63,434,000 | - | |
| Operating loss | -63,857,000 | -62,739,000 | - | |
| Investment and other income, net | 7,257,000 | 8,943,000 | - | |
| Net loss | -56,600,000 | - | - | |
| Unrealized (loss) gain on marketable securities | -229,000 | 254,000 | 3,508,000 | |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | - | - | |
| Net loss | - | -53,796,000 | -42,121,000 | |
| Comprehensive loss | -56,829,000 | -53,542,000 | -38,613,000 | |
| Earnings per share, basic | -0.85 | -0.81 | -0.64 | |
| Earnings per share, diluted | -0.85 | -0.81 | -0.64 | |
| Weighted average number of shares outstanding, basic | 66,392 | 66,383 | 66,294 | |
| Weighted average number of shares outstanding, diluted | 66,392 | 66,383 | 66,294 | |